Lactobacillus Microvesicles Protecting Beta Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Type 1 diabetes is characterized by the autoimmune destruction of insulin-producing beta cells in the pancreas, leading to the need for insulin injections and challenging blood sugar control, with current treatments focusing on insulin administration rather than addressing the underlying beta cell destruction.
Innovation Solution
The use of microvesicles (MVs) isolated from the naturally occurring probiotic Lactobacillus johnsonii strain N6.2, which are administered to reduce proinflammatory responses and inhibit apoptosis in human pancreatic beta cells, thereby potentially delaying the onset or progression of type 1 diabetes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If insulin administration is used to treat type 1 diabetes, then blood sugar control is achieved, but the underlying beta cell destruction is not addressed
Solution Approach 1:
Microvesicles derived from Lactobacillus johnsonii N6.2 serve as an intermediary agent that mediates protection against beta cell apoptosis. These microvesicles carry anti-apoptotic signals and anti-inflammatory factors that intervene in the autoimmune destruction process, providing a bridging mechanism between the probiotic bacteria and the protected beta cells
Solution Approach 2:
The treatment applies preliminary protective action to beta cells before complete destruction occurs. By administering microvesicles that prevent apoptosis and reduce proinflammatory responses, the treatment aims to preserve remaining beta cell function and potentially delay disease progression before insulin dependence becomes complete
2Reliability
If microvesicles from Lactobacillus johnsonii are administered to preserve beta cells, then beta cell function is protected, but the complexity of treatment increases
Solution Approach 1:
The active protective components are extracted from the complex Lactobacillus johnsonii N6.2 bacteria into isolated microvesicles. This extraction process separates the beneficial anti-apoptotic and anti-inflammatory elements from the entire bacterial system, creating a more targeted and potentially simpler treatment formulation that focuses on the specific protective mechanisms
Solution Approach 2:
The treatment utilizes changes in the physical and chemical parameters of the microvesicles, such as their size, surface properties, and cargo composition, to optimize their protective function. By controlling these parameters during microvesicle isolation and characterization, the treatment achieves enhanced beta cell protection while managing complexity through standardized biophysical parameters
Data Source
AI summary
A composition is provided herein, including microvesicles (MVs) isolated from a naturally occurring probiotic Lactobacillus sp. wherein the MVs are packaged in a capsule, emulsion, or tablet such that the packaged MVs are protected in a gastrointestinal tract for transport to an intestine of a subject. In another embodiment, a method for treating Type-1 diabetes including orally administering to a diabetic or pre-diabetic subject, or a subject at risk for becoming pre-diabetic or diabetic, a composition comprising an effective amount of microvesicles isolated from a naturally occurring probiotic strain comprising a Lactobacillus sp.i. In still a further embodiment, of improving immune function in a subject, comprising administering to the subject, the composition comprising an effective amount of microvesicles isolated from a naturally occurring probiotic Lactobacillus sp.